Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Barinthus Biotherapeutics (BRNS) Accumulated Expenses (2020 - 2025)

Barinthus Biotherapeutics (BRNS) has disclosed Accumulated Expenses for 6 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Accumulated Expenses fell 16.13% year-over-year to $6.7 million, compared with a TTM value of $6.7 million through Sep 2025, down 16.13%, and an annual FY2024 reading of $9.5 million, up 3.4% over the prior year.
  • Accumulated Expenses was $6.7 million for Q3 2025 at Barinthus Biotherapeutics, down from $7.4 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $11.9 million in Q3 2023 and bottomed at $9000.0 in Q2 2022.
  • Average Accumulated Expenses over 5 years is $6.0 million, with a median of $7.2 million recorded in 2025.
  • The sharpest move saw Accumulated Expenses plummeted 99.74% in 2022, then skyrocketed 35341.38% in 2024.
  • Year by year, Accumulated Expenses stood at $1.1 million in 2021, then skyrocketed by 651.96% to $8.1 million in 2022, then increased by 14.28% to $9.2 million in 2023, then grew by 3.4% to $9.5 million in 2024, then fell by 29.86% to $6.7 million in 2025.
  • Business Quant data shows Accumulated Expenses for BRNS at $6.7 million in Q3 2025, $7.4 million in Q2 2025, and $7.2 million in Q1 2025.